trial

Bifeprunox Extension to Extension Study in Patients With Schizophrenia

NCTId NCT00861497
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Terminated
Enrollment 11 (actual)
Sponsored by H. Lundbeck A/S
Primary completion 2008-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Terminated
Enrollment
11 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2006-01
Primary completion
2008-01
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Bifeprunox

Sponsors

H. Lundbeck A/SLead Sponsor
Solvay PharmaceuticalsCollaborator

Sites

1 total
Brescia, Italy

Linked catalysts

1
Bifeprunox Extension to Extension Study in Patients With Schizophrenia — primary completion2008-01

Facts & assertions

4 sourced
Enrollment
11
Phase
PHASE3
Primary Completion Date
2008-01
Status
TERMINATED
relationships
The graph out of here
drug
Bifeprunox
drug
lead_sponsor
H. Lundbeck A/S
company
collaborator
Solvay Pharmaceuticals
company
indication
Schizophrenia
indication
Schizophrenia
indication